Daily Equity Reports 29 Nov 2018

1. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647 DAILY EQUITY REPORT 28TH NOVEMBER 2018 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

2. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report INDIAN FACE INDIAN MARKET CLOSE PREVIOUS ! 35513.14 INDIAN EQUITY BENCHMARK :- At the close of market hours, the Sensex ended up 159.06 points or 0.45% at 10685.60 35513.14, while the Nifty was higher by 57.00 points or 0.54% ASIAN MARKET at 10685.60. The market breadth was narrow as 1238 shares CLOSE PREVIOUS advanced, against a decline of 1320 shares, while 161 shares NIKKEI 21952.40 21812 were unchanged.Infosys, TCS, and BPCL were the top gainers, 26331.96 while Sun Pharma and Hero MotoCorp lost the most. GLOBAL FACE 2083.02 SECTORIAL INDICES ! CLOSE CHANGE (%) Asian Market - Asian markets finished mixed as of the most recent closing prices. The Nikkei 225 gained 0.64%, while the Hang Seng led the Shanghai Composite lower. They fell 0.17% and 0.04% respectively. 10905.85 0.45 0.46 ! 0.45 U.S. Market – US futures under pressure as trade war concerns resurface. 0.46 ! .BANK NIFTY 26443.10 0.29 European markets - European markets are lower today with shares in London off the most. The FTSE 100 is down 0.30% while France's CAC 40 is off 0.18% and Germany's DAX is lower by 0.15%. CLOSE CHANGE (%) 641 3.15 3.00 349 2.71 2.65 TOP LOSERS CLOSE CHANGE (%) -3.84 -3.81 -3.03 -2.39 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

3. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report NIFTY SPOT MARKET MOVERS UPSIDE TREND STRATEGY SCRIPT CLOSE (%) 3.24 BEARISH COLPAL 1234.85 3.00 P R1 R2 10757 RESISTANCE R1-10750 R2-10850 R3 10856 MOTHERSUMI 10460 10559 10622 10658 10721 2.88 GAIL SUPPORT S1-10550 S2-10460 637 2.53 INFY CLOSE (%) -5.81 2050.70 PEL -3.34 -3.13 HEROMOTO CO 2966.60 -3.12 NET TREND BULLISH (CR.) 4756.12 S3 S2 S1 26283 P R1 R2 R3 25916 26146 26376 26513 DII 4276.96 SUPPORT S1-26280 S2-25900 RESISTANCE BANK NIFTY NSE TOTALS ADVANCE BANK NIFTY 7 5 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

4. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. Daily Equity Report MARKET TALKS ! Cadila gets final USFDA approval for ! IFCI up 5% on Binani Cement’s case resolution under IBC Shares of IFCI rose 5% on the news of resolution of Binani Cement’s case under the Insolvency and Bankruptcy Code (IBC).IFCI received Rs491.84cr towards the security receipts held by it in Binani Cements. On account of resolution of Binani Cements through the National Company Law Tribunal (NCLT), IFCI, which holds 42,16,850 security receipts of face value of Rs1,000/- each, has received an amount of Rs.491.84cr, net of TDS of Rs30.55cr, pursuant to the said resolution. Baclofen Tablets Cadila Healthcare has received a final approval from the US Food & Drug Administration (USFDA) to market Baclofen Tablets (US RLD- Lioresal®), 10 mg and 20 mg. Despite the news, shares of the company dropped 2% on Tuesday.The company will produce Baclofen Tablets from its formulations manufacturing facility at Baddi. These tablets are used to treat muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury/disease, the company said in a press note to the exchanges. ! Tech Mahindra receives order worth Rs270cr from Coal India: Media report Tech Mahindra has bagged an order worth Rs270cr for IT modernization project from Coal India, as per PTI report. Despite this, the company’s today.According to media report, an order includes supply and implementation of Hospital Information Management System, across all eight subsidiaries of Coal India covering 21 hospitals. shares fell 0.68% ! Alembic Pharma gets USFDA approval for Temazepam Capsules Alembic Pharmaceuticals, in a filing to the exchanges on Tuesday, announced that it has received an approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Temazepam Capsules USP (7.5mg, 15mg, 22.5mg, and 40mg)."The approved ANDA is therapeutically equivalent to the reference-listed drug product (RLD) Restoril Capsules (7.5mg, 15mg, 22.5mg, and 40mg), of SpecGx LLC. Temazepam Capsules are indicated for the short-term treatment of insomnia," the company said in a press note on Tuesday. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

5. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. DISCLAIMER The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Capitalstars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets are always subjected to market risk. Capitalstars Financial Research Private Ltd., Reserves all Rights. INVESTMENT AND TRADING IN SECURITIES MARKET IS ALWAYS SUBJECTED TO MARKET RISK. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

6. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. CapitalStars Financial Research Private Limited is an advisory company incepted with a vision of providing fair and accurate trading and investment calls in share and commodity market. we specialize in thorough fundamental and technical research analysis in equity and commodity market to provide best equity and commodity tips to traders and investors. we provide intraday as well as delivery stock tips in NSE and BSE and commodity tips in MCX and NCDEX. Get our more services:- Intraday stock tips Financial advisory company Share market company Stock Tips * Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance. * CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

7. CAPITALSTARS FINANCIAL RESEARCH PVT. LTD. BRANCH OFFICE Capitalstars Financial Research Private Limited PLOT NO.32, MECHANIC NAGAR EXTENSION,IDA SCHEME NO.54,VIJAYNAGAR INDORE REGISTERED OFFICE PLOT NO.12, SCHEME NO.78 PART-2, VIJAY NAGAR, INDORE Email:-backoffice@capiltalstars.in Report Is Checked by Investment Advisor: Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.